The DSC2 Knockout NCI-H1299 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population engineered to disrupt the DSC2 gene in the NCI-H1299 non-small cell lung cancer epithelial cell line. This polyclonal pool, derived from bulk editing without single-cell cloning, provides a heterogeneous loss-of-function model suitable for studying desmocollin-2-dependent processes in a metastatic lung adenocarcinoma background. The product enables researchers to interrogate DSC2 function without the constraints of clonal selection, capturing a representative range of gene-disruption events across the cell population. Standard quality control ensures robust target-gene disruption, making these cells immediately applicable for downstream functional assays and comparative analyses alongside parental or control NCI-H1299 cells.
The NCI-H1299 host cell line was originally established from a lymph node metastasis of a lung adenocarcinoma and is widely used as a model of invasive non-small cell lung cancer. These cells are characterized by their epithelial origin, TP53 deficiency, and a marked capacity for migration and invasion, reflecting key features of advanced tumor progression. Their metastatic derivation makes them particularly valuable for dissecting molecular mechanisms underlying dissemination and colonization. Within this context, DSC2 knockout provides a precise tool to assess the contribution of desmosomal adhesion to tumor cell behavior, including anchorage-independent growth, collective migration, and response to microenvironmental cues that promote metastasis.
DSC2 encodes desmocollin-2, a calcium-dependent desmosomal cadherin that mediates strong intercellular adhesion and maintains epithelial tissue integrity. As a core component of desmosomes, DSC2 interacts with desmosomal cadherin desmoglein-2 (DSG2) and recruits intracellular partners such as plakoglobin (JUP), plakophilin-2 (PKP2), and desmoplakin (DSP), which link the adhesive complex to cytokeratin intermediate filaments. Beyond mechanical cohesion, DSC2 participates in signaling networks: it modulates Wnt/??-catenin pathway activity, is regulated by TGF-?? and EGFR signaling, and influences downstream effectors including ??-catenin, plakoglobin, and desmoplakin. Disruption of DSC2 can destabilize desmosome assembly, alter ??-catenin transcriptional responses, and promote features of epithelial-mesenchymal transition (EMT). Key upstream regulators such as Wnt3a, AP-1 transcription factors, and TGF-?? converge on DSC2 expression, placing it at a critical junction between adhesion and proliferative signaling.
In the NCI-H1299 model, DSC2 knockout is expected to compromise desmosome-mediated cell-cell adhesion, potentially leading to weakened intercellular contacts and enhanced migratory and invasive properties. Loss of desmocollin-2 may shift ??-catenin signaling toward a transcriptional program that favors EMT, a process intimately linked to lung adenocarcinoma metastasis. Consequently, this knockout model offers a physiologically relevant platform to study desmosome-dependent tumor suppression, evaluate the interplay between adhesion complexes and oncogenic pathways, and explore mechanisms driving the transition from localized to disseminated disease. Moreover, the model connects to broader disease contexts, including arrhythmogenic right ventricular cardiomyopathy, palmoplantar keratoderma, and skin fragility disorders, where DSC2 dysfunction is implicated.
Typical research applications include Western blotting and RT-qPCR to confirm DSC2 ablation, immunofluorescence staining to visualize desmosomal protein distribution, and functional assays such as Transwell migration/invasion, cell adhesion, and TOP/FOP flash reporter assays to assess ??-catenin activity. These cells also support drug response profiling under DSC2-deficient conditions using MTT or related viability assays, enabling systematic evaluation of therapeutic vulnerabilities. Investigators studying EMT, tumor invasion, or desmosomal biology will find this tool valuable for dissecting molecular mechanisms and testing hypotheses in a disease-relevant cellular context. For additional technical details, assay protocols, or customization options, please contact Ascent Research.
